In KRAS mutant pancreatic ductal adenocarcinoma and lung adenocarcinoma, for example, it has been demonstrated in cell lines that the dependence on RAS signalling varies tremendously [46]. The gene discussed is KRAS; the disease is lung adenocarcinoma.